Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis
Open Access
- 1 October 2011
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (10), 4543-4551
- https://doi.org/10.1128/aac.00366-11
Abstract
E1210 is a first-in-class, broad-spectrum antifungal with a novel mechanism of action—inhibition of fungal glycosylphosphatidylinositol biosynthesis. In this study, the efficacies of E1210 and reference antifungals were evaluated in murine models of oropharyngeal and disseminated candidiasis, pulmonary aspergillosis, and disseminated fusariosis. Oral E1210 demonstrated dose-dependent efficacy in infections caused by Candida species, Aspergillus spp., and Fusarium solani . In the treatment of oropharyngeal candidiasis, E1210 and fluconazole each caused a significantly greater reduction in the number of oral CFU than the control treatment ( P < 0.05). In the disseminated candidiasis model, mice treated with E1210, fluconazole, caspofungin, or liposomal amphotericin B showed significantly higher survival rates than the control mice ( P < 0.05). E1210 was also highly effective in treating disseminated candidiasis caused by azole-resistant Candida albicans or Candida tropicalis . A 24-h delay in treatment onset minimally affected the efficacy outcome of E1210 in the treatment of disseminated candidiasis. In the Aspergillus flavus pulmonary aspergillosis model, mice treated with E1210, voriconazole, or caspofungin showed significantly higher survival rates than the control mice ( P < 0.05). E1210 was also effective in the treatment of Aspergillus fumigatus pulmonary aspergillosis. In contrast to many antifungals, E1210 was also effective against disseminated fusariosis caused by F. solani . In conclusion, E1210 demonstrated consistent efficacy in murine models of oropharyngeal and disseminated candidiasis, pulmonary aspergillosis, and disseminated fusariosis. These data suggest that further studies to determine E1210's potential for the treatment of disseminated fungal infections are indicated.Keywords
This publication has 39 references indexed in Scilit:
- In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and MoldsAntimicrobial Agents and Chemotherapy, 2011
- Synthesis and evaluation of novel antifungal agents-quinoline and pyridine amide derivativesBioorganic & Medicinal Chemistry Letters, 2010
- Factors Associated with Mortality in Transplant Patients with Invasive AspergillosisClinical Infectious Diseases, 2010
- Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk DiffusionJournal of Clinical Microbiology, 2010
- In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus SpeciesJournal of Clinical Microbiology, 2008
- In Vitro and In Vivo Antifungal Activities of T-2307, a Novel ArylamidineAntimicrobial Agents and Chemotherapy, 2008
- Fusarium Infections in Immunocompromised PatientsClinical Microbiology Reviews, 2007
- Multiple-Triazole–Resistant AspergillosisThe New England Journal of Medicine, 2007
- International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003)Journal of Clinical Microbiology, 2006
- In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2003